<DOC>
	<DOCNO>NCT01967641</DOCNO>
	<brief_summary>In study , assess opioid self-administration laboratory set person pain history opioid abuse . Participants diagnose mild moderate pain admit hospital 7 week transition baseline prescription opioid stand daily dose Suboxone ( buprenorphine/naloxone combination ) . During maintenance period , participant opportunity laboratory set self-administer oxycodone ; subjective response well analgesic , physiological performance effect measure . In second phase study , patient participate inpatient phase follow outpatient basis maintain Suboxone 12 week . . The hypothesis study ( 1 ) high progressive ratio break-point value oxycodone , high subjective rating euphoria , less pain relief predict early relapse opioid abuse ; ( 2 ) abuse liability measure strongly correlate relapse pain measure ; ( 3 ) subjective rating euphoria increase pain decrease oxycodone dose-dependent manner ( i.e . euphoria increase pain decrease dose increase ) ; ( 4 ) experimentally induced pain decrease oxycodone dose-dependent manner .</brief_summary>
	<brief_title>Prescription Opioid Abuse Among Pain Patients : Predictors Relapse</brief_title>
	<detailed_description>All participant admit GCRU , SRU , CRR maintain sublingual Bup/Ntx . During first week admission , participant withdraw prior opioid analgesic regimen stabilize one three dose buprenorphine/naloxone ( 2/0.5 , 8/2 , 16/4 mg per day ) . Participants treat emergent withdrawal symptom supplemental supplemental medication ( clonidine , clonazepam , compazine , ketorolac tromethamine , hydroxyzine , ranitidine , ondansetron , zolpidem ) withdrawal symptom dissipate , base self-report observer rating . Each buprenorphine dose administer equal divided dos accord QID dosing schedule , dose maintain two-week period ( one week stabilization follow one week laboratory test ) . Thus , stabilization occur Weeks 1 , 3 , 5 ; test occur Weeks 2 , 4 , 6 . Participants may receive unaccompanied pas 72 hour Weeks 3 5 attend family obligation . Participants informed urine toxicology screen conduct upon return hospital , test positive drug study medication may result discharge study . The order administration three dos vary among subject randomize manner . At completion laboratory test Week 6 , participant stabilize 16 mg buprenorphine . This final week stabilization ensures ( 1 ) acute effect high-dose oxycodone administration laboratory dissipate affect opioid dependence level ; ( 2 ) participant sufficient opportunity stabilize dose buprenorphine maintain outpatient phase . Participants whose pain adequately relieve Suboxone ( buprenorphine/naloxone ) remove study investigator . A criterion dropout inpatient phase : clear decline functional status , sustain worsen mobility mark decline level activity . In event average daily pain level worsen baseline 30 % ( e.g . 6/10 9/10 ) , clinical evaluation perform consider whether participant remove protocol , allow continue participate . The clinical determination include assessment whether pain improve throughout inpatient stay range dos test . During subsequent outpatient phase medication dispense weekly basis consist ( 1 ) stand maintenance dose 16 mg Suboxone ( buprenorphine/naloxone ) , ( 2 ) dose Suboxone take prn basis breakthrough pain ( prn dos exceed 25 % total daily stand dose ) . Patients report Substance Use Research Center ( SURC ) twice per week 12 week clinical visit .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>1 . DSMIV criterion opioid abuse prescription opioid physical dependence 2 . 1865 year age 3 . Stable weight ( &lt; 10 % change 3 month ) stable physical health 4 . Chronic pain syndrome ( e.g. , osteoarthritic pain chronic low back pain with/without history surgery ) moderate ( 47 ) average daily pain 6+ month duration ; opioid medication maintenance 6+ month 5 . Seeking treatment chronic pain 6 . Must expect achieve good analgesic effect buprenorphine 1 . DSMIV untreated Axis I disorder ( e.g . MDD , BAD , psychotic disorder , eat disorder ) require treatment 2 . Regular consumption 500 mg caffeine daily 3 . Primary pain diagnosis neuropathic pain , malignant pain , headache 4 . History allergy , adverse reaction , sensitivity opioids , include buprenorphine 5 . Pregnancy , lactation , history give birth abortion miscarriage within last six month , unwillingness use effective method birth control ( e.g . condom , birth control pill , abstinence ) 6 . Psychotropic medication would potentially interfere study procedure 7 . Inability read understand selfreport assessment form unaided 8 . Use medication know interfere buprenorphine metabolism , disulfiram , neuroleptic , azole antifungal ( e.g . ketoconazole ) , macrolide antibiotic ( e.g . erythromycin ) , HIV protease inhibitor ( e.g . ritonavir , indivair , saquinavir ) 9 . Methadonedependent 10 . Current heroin dependence 11 . Current buprenorphine maintenance 12 . History fail treatment buprenorphine maintenance pain 13 . Acute hepatitis elevate liver function test ( i.e . AST ALT &gt; 3 time upper limit normal ) impair renal function ( creatinine &gt; 1.2 ) 14 . Any medical condition might interfere study significantly increase medical risk study participation 15 . Participant currently receive investigational drug use investigational drug within 30 day study entry 16 . History significant cardiovascular disease , coronary artery disease hypertension require two antihypertensive agent 17 . History insulindependent diabetes 18 . Body mass index &lt; 18.5 &gt; 35.0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>opioid dependence</keyword>
	<keyword>opioid abuse</keyword>
	<keyword>suboxone</keyword>
	<keyword>prescription pain medication</keyword>
</DOC>